

Table 1: Top 40 Funders of TB R&D in 2005 Reported to TAG by October 2006
 (see Appendix A for investments by research category)

Rank	Donor	Total
1	NIAID / NIH	120,273,000
2	Gates Foundation	57,411,457
3	Medical Research Council (UK)	30,887,839
4	Other Institutes & Centers / NIH	20,334,300
5	Centers for Disease Control	19,903,000
6	Company X	18,640,160
7	Wellcome Trust	18,081,359
8	NHLBI / NIH	17,117,000
9	European Commission 6th Framework	13,322,711
10	Otsuka	12,300,000
11	Institut Pasteur	8,472,800
12	AstraZeneca	8,000,000
13	USAID	6,694,000
14	Inserm	5,721,560
15	TB Research Center (ICMR), India	5,313,133
16	Ministry of Science and Technology, India	3,168,488
17	Netherlands Ministry of Foreign Affairs (DGIS)	3,168,488
18	Max Planck Institute	2,500,000
19	Canadian Institute of Health Research	2,376,098
20	Novartis	2,255,193
21	Department for International Development (DFID)	2,008,832
22	Russian TB Institutes*	1,930,343
23	Rockefeller Foundation	1,750,000
24	Ellison Medical Foundation	1,650,000
25	Global Fund to Fight AIDS, Tuberculosis and Malaria**	1,648,083
26	Research Institute for TB, Japan Anti-TB Association	1,487,961
27	Sequella***	1,400,000
28	Brazil (in aggregate)	755,587
29	Food and Drug Administration	651,231
30	Company Y	500,000
31	Swedish International Development Agency	486,599
32	Development Cooperation of Ireland	360,000
33	Ministry of Public Health, TB Cluster, Thailand	287,050
34	Netherlands Organization for Scientific Research (N.W.O.)	199,716
35	Swiss Agency for Development and Cooperation	195,099
36	KNCV Tuberculosis Foundation	170,666
37	Danish International Development Agency (Danida)	170,344
38	All India Institute of Medical Sciences	154,821
39	Ministry of Foreign Affairs, France	127,092
40	Eli Lilly Foundation	113,660
	TOTAL	\$392,713,089

* Aggregate spending of four Russian Federation TB institutes.
 ** Global Fund figures estimated based on their reported activities.
 *** Sequella spent \$3.5 million; \$2.1 million from NIH not counted twice.